Osimertinib vs Tildrakizumab
Osimertinib vs Tildrakizumab: Overview
This comparison examines the pharmacological differences between Osimertinib and Tildrakizumab.
Mechanism of Action
Osimertinib: Third-generation irreversible EGFR TKI targeting T790M resistance mutation and activating mutations.
Pharmacokinetics
Half-life: Osimertinib β 48 hours.
Chemical Properties
Molecular Formula: Osimertinib β C28H33N7O2.
Molecular Weight: Osimertinib β 499.6050 g/mol.
Type: Osimertinib β Small molecule; Tildrakizumab β Antibody.